AVEO Oncology Completes First Analysis of FIERCE-HN Study for Head and Neck Cancer Treatment AVEO Oncology announces the successful completion of the first interim analysis for the global FIERCE-HN study, focusing on a promising combination therapy for patients with advanced head and neck cancer.

AVEO Oncology Completes First Analysis of FIERCE-HN Study for Head and Neck Cancer Treatment #United_States #Boston #AVEO_Oncology #HNSCC #ficlatuzumab

AVEO Oncology Marks Milestone with First Patient Dosing in AML Study of Ficlatuzumab AVEO Oncology has announced the successful dosing of the first patient in a clinical trial for treating AML with ficlatuzumab, in partnership with Blood Cancer United.

AVEO Oncology Marks Milestone with First Patient Dosing in AML Study of Ficlatuzumab #USA #Boston #AVEO_Oncology #Blood_Cancer_United #ficlatuzumab

AVEO Oncology and HiberCell Sign Agreement for Innovative Cancer Treatment Development AVEO Oncology and HiberCell have partnered to develop a groundbreaking first-in-human PERK inhibitor, HC-5404, to enhance renal cell carcinoma treatments together with FOTIVDA.

AVEO Oncology and HiberCell Sign Agreement for Innovative Cancer Treatment Development #United_States #Boston #AVEO_Oncology #HiberCell #HC-5404

AVEO Oncology Unveils Innovative Cancer Treatment Findings at ASCO 2025 AVEO Oncology showcased significant advancements in cancer treatments with three pivotal posters at ASCO 2025, reflecting their commitment to improving patient lives.

AVEO Oncology Unveils Innovative Cancer Treatment Findings at ASCO 2025 #United_States #Chicago #cancer_therapies #AVEO_Oncology #Tivozanib

AVEO Oncology to Present Groundbreaking Cancer Research at ASCO 2025 AVEO Oncology, a subsidiary of LG Chem, announces three significant poster presentations at ASCO 2025, showcasing innovative cancer treatments and research advancements.

AVEO Oncology to Present Groundbreaking Cancer Research at ASCO 2025 #USA #Chicago #LG_Chem #AVEO_Oncology #Tivozanib

AVEO Oncology Unveils Promising Tivozanib Data at ASCO GU 2025 AVEO Oncology, a subsidiary of LG Chem, presents two crucial posters on Tivozanib, highlighting its efficacy and patient benefits during the 2025 ASCO GU meeting.

AVEO Oncology Unveils Promising Tivozanib Data at ASCO GU 2025 #USA #Boston #ASCO_2025 #AVEO_Oncology #Tivozanib

AVEO Oncology Reveals Key Findings on Tivozanib at ASCO GU 2025 Conference AVEO Oncology is set to showcase significant research findings on Tivozanib at the ASCO GU 2025 meeting in San Francisco. Key presentations will highlight advancements in renal cell carcinoma treatment.

AVEO Oncology Reveals Key Findings on Tivozanib at ASCO GU 2025 Conference #USA #San_Francisco #ASCO_GU #AVEO_Oncology #Tivozanib